MARKET

ICAD

ICAD

ICAD US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.48
+0.27
+2.41%
After Hours: 11.48 0 0.00% 16:00 10/23 EDT
OPEN
11.38
PREV CLOSE
11.21
HIGH
11.88
LOW
11.20
VOLUME
214.27K
TURNOVER
--
52 WEEK HIGH
15.31
52 WEEK LOW
5.91
MARKET CAP
262.90M
P/E (TTM)
-11.2693
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer TumorsNASHUA, N.H., Oct. 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at the American Society for Radiation Oncology (ASTRO) Virtual Annual Meeting, October 24-28, 2020. Researchers will present new data supporting the Xoft System for the treatment of early-stage breast cancer and gynecological cancers, as the Company showcases the latest in technology for Xoft including its full suite of applicators for existing and emerging applications in the virtual Xoft exhibition booth. “The Xoft System offers the flexibility to treat multiple types of cancers within the same facility, with added mobility, and time-savings benefits for patients and clinicians alike,” according to Michael Klein, Chairman and CEO of iCAD. “This innovative treatment platform offers a one-step targeted treatment option for early-stage breast cancer and certain types of brain tumors, which may contribute to a reduction in the healthcare system resources needed for breast cancer patients during the COVID-19 pandemic while also offering significant cost benefits for patients.”The Xoft System is a 50 kV radiation oncology treatment solution that uses a miniaturized X-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site while minimizing risk of damage to healthy tissue in nearby areas of the body. The isotope-free radiation requires minimal shielding, enabling medical professionals to remain in the room during treatment.A growing body of evidence continues to support the Xoft System across multiple cancer types. During the meeting, researchers will present new data supporting the Xoft System for early-stage breast cancer and endometrial cancers: * “Intra-Operative Electronic Brachytherapy in the Treatment of Early Stage Breast Cancer – A Multi-Center Trial, Technique and Preliminary Results,” presented by A.M. Nisar Syed, MD, Radiation Oncology, Todd Cancer Institute, MemorialCare Long Beach Medical Center involved 1,200 patients with early-stage breast cancer treated with Xoft IORT from May 2012 to July 2018 across 27 institutions worldwide. Researchers concluded that IORT with the Xoft System is safe, with low morbidity, low local recurrence and excellent cosmetic results. * “Adjuvant Electronic Brachytherapy for Patients with Endometrial Cancer,” presented by Arantxa Campos, MD, examined the results of treating 236 patients with endometrial cancer from September 2015 to May 2020, with a median follow up of 34 months. Researchers concluded that Xoft electronic brachytherapy is a feasible alternative to HDR brachytherapy for the treatment of endometrial cancer that offers long-term benefits for patients, staff and the overall health system. iCAD will also host virtual discussions with Drs. Syed and Campos with updates on their latest research for eBx and IORT with the Xoft System. Register to join via: https://www.xoftinc.com/astro2020.html.“Our ongoing research with the Xoft System for early-stage breast cancer corroborates the mounting long-term evidence supporting 50 kV IORT as a treatment option that is as effective as weeks of daily radiation fractions,i,ii” according to Dr. Syed. “Xoft IORT can spare patients who are candidates from the need to make multiple trips to the hospital for treatment, with the added benefit of fewer side effects and comparable recurrence rates. It not only offers added convenience for women, especially those living in remote areas who must travel great distances for radiation, it may be particularly comforting for women who want to minimize their potential risk of COVID-19 exposure.”Earlier this week, new, encouraging research supporting the Xoft System for the treatment of recurrent glioblastoma (GBM) was presented at the European Association of Neurosurgical Societies (EANS) Virtual Congress by Alexey Gaytan, MD, PhD, a neurosurgeon at the European Medical Center (EMC) in Moscow, Russia. The latest results demonstrate significant improvement in overall survival (OS) and local progression-free survival (locPFS) in patients with recurrent GBM treated with Xoft Intraoperative Radiotherapy (IORT) versus patients treated with external beam radiation therapy (EBRT) and systemic therapy.The study, under the guidance of Lead Investigator, Alexey Krivoshapkin, MD, PhD, a neurosurgeon at the EMC, involves 28 patients with recurrent GBM who were treated between August 2016 and June 2019. All patients underwent maximal safe resection. Researchers concluded that IORT of recurrent GBM is feasible and provides encouraging local progression-free and overall survival, with a manageable toxicity profile, and that further clinical trials are warranted.As of May 2020, 5 patients from the IORT group were still alive, whereas none of the patients in the EBRT group survived. Our earlier release of January survival data included 7 patients surviving as of mid-December 2019. The survival of patients in the IORT group ranged from 16 – 59 months after the initial GBM diagnosis. As previously disclosed, the EBRT group survival ranged from 5.5 – 38.5 months after initial GBM diagnosis.In addition, the first metastatic brain tumor was treated with IORT in the U.S. using the Xoft System at the James Graham Brown Cancer Center at the University of Louisville. The procedure marked the start of a clinical trial on IORT for patients with large brain metastases treated with neurological resection, led by Shiao Yuo Woo, MD, FACR, radiation oncologist at the James Graham Brown Cancer Center.iiiiCAD recently assembled a panel of experts to expand research on Xoft Brain IORT to multiple leading cancer centers worldwide. The Company is also exploring other emerging applications for the Xoft System, including the treatment of early-stage rectal tumors.“The Xoft System remains a leading force in the trend towards more personalized cancer treatment,” added Klein. “As cancer treatment becomes increasingly targeted and value-based, we will continue to work with the clinical community to explore and advance cancer treatment, with the goal of improving outcomes, increasing treatment accessibility and offering unparalleled value for clinicians and patients alike.”About iCAD, Inc.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.For more information, visit www.icadmed.com and www.xoftinc.com.Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the ability of IORT to provide flexibility, mobility or other advantages, to be more beneficial for patients than traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at https://www.sec.gov.Media Inquiries: Maria Stanieich, iCAD +1 (603) 309-1949Investor Relations: Jeremy Feffer, LifeSci Advisors +1 (212) 915-2568 jeremy@lifesciadvisors.com* * *i Silverstein, M.J., Epstein, M., Kim, B. et al. Intraoperative Radiation Therapy (IORT): A Series of 1000 Tumors. Ann Surg Oncol 25, 2987–2993 (2018). https://doi.org/10.1245/s10434-018-6614-3 ii Vaidya, JS et al. (2020). Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ 2020;370:m2836 Accessed via https://doi.org/10.1136/bmj.m2836 iii University of Louisville. Study of Intraoperative Radiotherapy for Patients With Large Brain Metastases Treated With Neurosurgical Resection. Accessed via https://clinicaltrials.gov/ct2/show/NCT04040400. ClinicalTrials.gov Identifier: NCT04040400.
GlobeNewswire · 1d ago
iCAD, Inc. (NASDAQ:ICAD): Are Analysts Optimistic?
iCAD, Inc. (NASDAQ:ICAD) is possibly approaching a major achievement in its business, so we would like to shine some...
Simply Wall St. · 2d ago
Matinas Reports Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Matinas BioPharma reports progress for EnACT study of MAT2203.iCAD announces positive data for Xoft in recurrent glioblastoma.AbbVie receives full FDA approval for Venclexta.
Seekingalpha · 3d ago
iCAD Signs Distribution Agreement with Change Healthcare To Expand Access To ProFound AI™ For More Hospitals And Imaging Centers Across North America
iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a distribution agreement with Change Healthcare (NASDAQ:CHNG), a
Benzinga · 4d ago
iCAD' Xoft radiotherapy shows survival improvement in recurrent brain tumors treatment
 iCAD ([[ICAD]] +2.3%) announces latest data demonstrating significant improvement in overall survival and local progression-free survival in patients with recurrent glioblastoma ((GBM)) treated with Xoft Intraoperative Radiotherapy ((IORT)) against external beam radiation therapy ((EBRT)). The
Seekingalpha · 5d ago
iCAD Highlights Presentation Of Clinical Results Supporting Xoft Axxent Electronic Brachytherapy System For Recurrent Glioblastoma
NASHUA, N.H., Oct. 19, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new, promising clinical
Benzinga · 5d ago
New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma
New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of NeurosurgeryNASHUA, N.H., Oct. 19, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new, promising clinical results supporting the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of recurrent glioblastoma (GBM), will be presented at the European Association of Neurosurgical Societies (EANS) Virtual Congress, October 19- 21, 2020. New Data from the ongoing prospective study, entitled “Four-year experience of maximal safe resection with intraoperative balloon electronic brachytherapy for recurrent glioblastoma,” (AS-EANS-2020-00135) will be presented by Alexey Gaytan, MD, PhD, a neurosurgeon at the European Medical Center (EMC) in Moscow, Russia. The latest results demonstrate significant improvement in overall survival (OS) and local progression-free survival (locPFS) in patients with recurrent GBM treated with Xoft Intraoperative Radiotherapy (IORT) versus patients treated with external beam radiation therapy (EBRT) and systemic therapy.“The latest results are extremely encouraging, as they underscore the potential of Xoft IORT for recurrent glioblastoma while illustrating the impact our innovative technology may have on the treatment of the most aggressive primary brain tumors,” said Michael Klein, Chairman and CEO of iCAD. “GBM has a median survival of 10-12 monthsi,ii and almost 297,000 cases of brain and nervous system tumors are diagnosed worldwide each year,iii with inevitable recurrence; however, this data is promising and may offer hope to patients and their families.”The study, under the guidance of Lead Investigator, Alexey Krivoshapkin, MD, PhD, a neurosurgeon at the EMC, involves 28 patients with recurrent GBM who were treated between August 2016 and June 2019. All patients underwent maximal safe resection. Researchers concluded that IORT of recurrent GBM is feasible and provides encouraging local progression-free and overall survival, with a manageable toxicity profile, and that further clinical trials are warranted.As of May 2020, 5 patients from the IORT group were still alive, whereas none of the patients in the EBRT group survived. Our earlier release of January survival data included 7 patients surviving as of mid-December 2019. The survival of patients in the IORT group ranged from 16 – 59 months after the initial GBM diagnosis. As previously disclosed, the EBRT group survival ranged from 5.5 – 38.5 months after initial GBM diagnosis.“We continue to be greatly encouraged by these clinical results and the benefits this treatment offers to patients with GBM,” said Professor Krivoshapkin. “There is no standard approach on how to treat patients with recurrent GBM and the repeated use of EBRT in recurrent brain tumors is often limited by a relatively high risk of radiation toxicity. Intraoperative balloon electronic brachytherapy has the potential to deliver the required prescribed single focal dose that is equivalent to multiple sessions of EBRT while minimizing radiation dose to neighboring healthy tissue.”iCAD recently assembled a panel of experts to expand research on Xoft Brain IORT to multiple leading cancer centers worldwide. The Company is also exploring other emerging applications for the Xoft System, including the treatment of early-stage rectal tumors.The Xoft System is a 50 kV radiation oncology treatment solution that uses a miniaturized X-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site while minimizing risk of damage to healthy tissue in nearby areas of the body. The isotope-free radiation requires minimal shielding, enabling medical professionals to remain in the room during treatment.About iCAD, Inc.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.For more information, visit www.icadmed.com and www.xoftinc.com.Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the ability of IORT to provide flexibility, mobility or other advantages, to be more beneficial for patients than traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at https://www.sec.gov.Media Inquiries: Amy Cook, iCAD +1 (925) 200-2125 acook@icadmed.comInvestor Relations: Jeremy Feffer, LifeSci Advisors +1 (212) 915-2568 jeremy@lifesciadvisors.com 1. Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 8. Accessed via https://www.ncbi.nlm.nih.gov/books/NBK470003. 2. Pan E, Prados MD. Glioblastoma Multiforme and Anaplastic Astrocytoma. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Accessed via https://www.ncbi.nlm.nih.gov/books/NBK12526/. 3. WHO, IARC, Globocan Cancer Incidence and Mortality Worldwide in 2018. Accessed via https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
GlobeNewswire · 5d ago
iCAD Hosting Technology Innovation Webinar on the Evolving Landscape for Treating Patients with Brain, Breast, and Rectal Cancers
Webinar Taking Place on Wednesday, October 21st @ 10amETNASHUA, N.H., Oct. 16, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host a technology innovation webinar on the current treatment landscape and unmet medical needs for treating cancer, on Wednesday, October 21, 2020, at 10am Eastern Time. The call will feature presentations by key opinion leaders Santosh Kesari, MD, PhD, John Wayne Cancer Center, Janie Grumley, MD, FACS, John Wayne Cancer Center and Té Vuong, MD, B.Sc., Fountain Valley Regional Hospital & Medical Center, who will discuss the current treatment landscape and new innovative methods for treating patients with cancers such as glioblastoma (GBM), breast and rectal.iCAD's management team will provide an update on innovations across the detection and therapy businesses, including an overview of iCAD’s breast cancer risk-assessment solution, a key element in the transformation from age-based screening to risk-adaptive screening. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as a viable treatment option for GBM. The management team, along with Drs. Vuong and Santosh will be available to answer questions following the formal presentations.To register for the event, please click here.Janie Grumley, MD, FACS, is the Director, Comprehensive Breast Program, Director at Margie Petersen Breast Center and John Wayne Cancer Institute. She is a surgical breast oncologist who has expertise in treating patients with breast cancer and benign breast diseases. She specializes in novel treatments such as oncoplastic breast-conserving surgery and intraoperative radiation therapy. Dr. Grumley found her path in her third year of residency at the University of Southern California when she met a surgical breast oncologist who was transforming breast cancer care with the use of oncoplastic surgery. She was inspired by the difference these techniques made in women’s lives during and after treatment.Té Vuong, MD, B.Sc., received her M.D. from the Université de Montréal and continued her postgraduate training in radiation oncology at the University of Toronto and the Institut Gustave Roussy and Institut Curie in Paris, France.She is a Professor at McGill University in the Department of Oncology, where she also holds the position of Assistant Chair, Radiation Oncology. She was appointed Director, Radiation Oncology of the Segal Cancer Centre at the Jewish General Hospital in August 2009.Dr. Vuong is internationally recognized, particularly for her expertise in the treatment and research of rectal cancer. Her current research focus is on high dose rate endorectal brachytherapy for patients with rectal cancer. Her expertise makes her a sought-after lecturer in both the academic and scientific communities. Her publications appear in internationally renowned scientific journals.Dr. Vuong conducts cutting-edge research in the area of colorectal cancer. She has engaged in numerous studies throughout her career, as either the Principal Investigator or a co-participant. Her efforts have led to the development of new radiation technologies and clinical protocols for the treatment of gastrointestinal cancer.Santosh Kesari, MD, PhD, is a board-certified neurologist and neuro-oncologist and is currently Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute. He is also Director of Neuro-oncology at Pacific Neuroscience Institute, Providence Saint John’s Health Center and Providence Little Company of Mary Medical Center Torrance, and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech startups. In addition, he is a member of the Los Angeles Biomedical Research Institute.About iCAD, Inc. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.The Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.For more information, visit www.icadmed.com and www.xoftinc.com.Forward-Looking Statements Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the ability of IORT to provide flexibility, mobility or other advantages, to be more beneficial for patients than traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at https://www.sec.gov.Contacts: Media inquiries: Jessica Burns, iCAD   +1-201-423-4492 jburns@icadmed.comAmy Cook, iCAD acook@icadmed.comInvestor Relations: Jeremy Feffer, LifeSci Advisors +1-212-915-2568 jeremy@lifesciadvisors.com
GlobeNewswire · 10/16 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICAD. Analyze the recent business situations of ICAD US through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICAD stock price target is 14.70 with a high estimate of 16.00 and a low estimate of 13.50.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 11.27M
% Owned: 49.23%
Shares Outstanding: 22.90M
TypeInstitutionsShares
Increased
29
2.79M
New
45
946.40K
Decreased
18
1.09M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.20%
Healthcare Equipment & Supplies
+0.12%
Key Executives
Chairman/Chief Executive Officer/Executive Director/Director
Michael Klein
President
Stacey Stevens
Chief Financial Officer
R. Scott Areglado
Chief Technology Officer
Jonathan Go
Independent Director
Nathaniel Dalton
Independent Director
Rakesh Patel
Independent Director
Andrew Sassine
Independent Director
Susan Wood
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ICAD
iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of iCAD Inc stock information, including NASDAQ:ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICAD stock methods without spending real money on the virtual paper trading platform.